CVRx has added an additional approximate $17.7 million to a previous funding round, according to a recently posted SEC filing from the company.
In the equity financing round, which notes its first date of sale as having occurred on May 31, 2016, the Minneapolis-based company reported raising approximately $75.4 million of a total hoped for $93 million.
Money in the offering came from 20 unnamed investors, according to the SEC filing.
CVRx said that the remaining approximate $17.7 million has “already been subscribed by existing investors and the sale of such securities will close when determined by the company’s board of directors,” according to the filing.
Last month, a CVRx-sponsored study involving more than 400 patients suggested that the company’s baroreflex activation therapy showed some promise treating heart failure.
DeviceTalks Minnesota's leadership track is designed to provide attendees with insights on topics such as:
Use code SAVE15 to save 15%!